Results 111 to 120 of about 178,847 (197)
PD-L1 in ICI Myocarditis: When the Immune Brake Fails. [PDF]
Chen AC, Moslehi JJ.
europepmc +1 more source
Radiotherapy‐treated tumor membranes are integrated with Mn‐MOF nanoadjuvants to generate Mn@RM, a lymph node‐draining nanovaccine that delivers radiotherapy‐remodeled antigenic components. Mn@RM enhances dendritic cell activation, amplifies T cell‐mediated antitumor immunity, and synergizes with radiotherapy and PD‐1 blockade for combination cancer ...
Yiyu Wang +8 more
wiley +1 more source
A bibliometric analysis of resistance to PD-1/PD-L1 inhibitors. [PDF]
Miao L, Jiang Z.
europepmc +1 more source
The TPR‐LYTACs nanomaterial offers a dual‐pathway strategy for precise gouty arthritis treatment by targeting and degrading the ROS‐producing enzyme NOX2 inside macrophages while its antioxidant core clears accumulated ROS outside. This “source inhibition and microenvironment scavenging” approach, guided by NIR‐II imaging, effectively controls local ...
Jian Zhang +15 more
wiley +1 more source
Enhancing Non-small Cell Lung Cancer Susceptibility to Anti-PD-1/PD-L1 Therapy through PD-L1 Ligand-Ir(III) Complex Conjugates. [PDF]
Pagliara V +17 more
europepmc +1 more source
We identified a Krt14+ Igf2bp1+ bladder cancer population linked to EMT. Mechanistically, KRT14 stabilizes and transports IGF2BP1 to invasive protrusions, initiating a positive feedback loop that drives metastasis and poor outcomes. ABSTRACT Basal‐type muscle‐invasive bladder cancer (BMIBC) is characterized by aggressive metastasis and poor prognosis ...
Shirui Huang +19 more
wiley +1 more source
PDIA6–SCD1 Axis Rewires Lipid Metabolism to Drive Gastric Cancer Progression
Protein disulfide isomerase A6 (PDIA6) is identified as an oncogenic driver in gastric cancer. PDIA6 directly binds and stabilizes SCD1 by limiting its ubiquitin–proteasome‐mediated degradation, thereby sustaining monounsaturated fatty acid (MUFA)‐enriched lipid homeostasis and lipid metabolic reprogramming.
Zhen Tian +13 more
wiley +1 more source
Nuclear PD-L1: an emerging oncogenic driver and promising therapeutic target in cancer. [PDF]
Guo C +5 more
europepmc +1 more source
This study introduces a foundation model‐based biomarker for risk stratification of pathological response in non‐small cell lung cancer. A Vision Mamba super‐resolution model standardizes heterogeneous CT images. A multi‐task Swin Transformer then fine‐tunes a pre‐trained lung foundation model to jointly optimize tumor segmentation and response ...
Yanglan Xu +10 more
wiley +1 more source
Overcoming resistance to anti-PD-1/PD-L1 therapy in cancer. [PDF]
Li L +8 more
europepmc +1 more source

